Drug Trial Radar · NCT06125522
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
Jan 10, 2024
Primary completion
Sep 10, 2026
Study completion Sep 10, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Arvinas Estrogen Receptor, Inc.; Carrick Therapeutics Limited; Rigel Pharmaceuticals,Inc.
- First posted
- Nov 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine called vepdegestrant. The safety and effects of vepdegestrant will be see when given with other medicines. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. This study is divided into separate sub-studies. For Sub-Study C: All the participants will receive vepdegestrant and a medicine called samuraciclib. Vepdegestrant and samuraciclib will be taken once in a day by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicine is safe and effective. Participant will continue to take vepdegestrant and samuraciclib until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Conditions
- Breast Cancer
Interventions
vepdegestrantDrug
Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
SamuraciclibDrug
Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants With Dose Limiting ToxicitiesTime frame: 28 days
- Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
- Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
- Phase 2: Percentage of Participants With Objective Response by investigator assessmentTime frame: Up to approximately 1 year
- Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))
- Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
Highlands Oncology Group
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
Clinical and Translational Research Unit (CTRU)
Palo Alto, California
Stanford Cancer Institute - Clinical Trials Office
Palo Alto, California
Stanford Women's Cancer Center
Palo Alto, California
UCHealth Poudre Valley Hospital
Fort Collins, Colorado
UCHealth Harmony
Fort Collins, Colorado
UCHealth Greeley Hospital
Greeley, Colorado
UCHealth - Medical Center of the Rockies
Loveland, Colorado
Memorial Hospital East
Shiloh, Illinois
Siteman Cancer Center - Shiloh
Shiloh, Illinois
Siteman Cancer Center - St Peters
City of Saint Peters, Missouri
Siteman Cancer Center - West County
Creve Coeur, Missouri
Siteman Cancer Center - North County
Florissant, Missouri
Barnes-Jewish Hospital
St Louis, Missouri
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center - South County
St Louis, Missouri
Institut Jules Bordet
Anderlecht, Bruxelles-capitale, Région de, Belgium
Centre Georges François Leclerc
Dijon, Côte-d'or, France
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Roma, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.